Translational Development Acquisition (TDACW) Operating Expenses (2023 - 2026)

Translational Development Acquisition (TDACW) has reported Operating Expenses for 4 consecutive years, with $661050.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 198.95% year-over-year to $661050.0; the trailing twelve-month figure through Jun 2026 stood at $1.3 million (up 72.72% YoY), and the FY2025 full-year result was $944538.0, up 381.03% from the prior year.
• Operating Expenses improved to $661050.0 in Q2 2026 per TDACW's latest filing, from $281161.0 in the prior quarter.
• Across five years, Operating Expenses topped out at $661050.0 in Q2 2026 and bottomed at $61283.0 in Q3 2024.
• Historically, Operating Expenses has averaged $285219.1 across 4 years, with a median of $221127.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 72.53% in 2024, then jumped 248.64% in 2025.
• Over 4 years, Operating Expenses stood at $485550.0 in 2023, then sank by 72.53% to $133390.0 in 2024, then increased by 21.71% to $162345.0 in 2025, then soared by 307.19% to $661050.0 in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $661050.0, $281161.0, and $162345.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.